Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma.
Falco
Patrizia
P
Bertola
Alessandra
A
Bringhen
Sara
S
Cavallo
Federica
F
Boccadoro
Mario
M
Palumbo
Antonio
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004351:Drug Resistance; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D017713:Platelet Transfusion; D011241:Prednisone / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D012008:Recurrence; D013792:Thalidomide / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D013792:Thalidomide; D008558:Melphalan; D011241:Prednisone